AbbVie agrees a $200 million-plus takeover deal with Roche spinout Nimble Therapeutics that will add an oral peptide for psoriasis to its pipeline. Join the conversation, on Tuesday 28th January ...
Polaris Capital Management, an investment management company, released its third quarter 2024 investor letter. A copy of the ...
Hosted on MSN16d
2 Excellent Dividend Stocks to Buy on the DipRecently AbbVie closed its acquisition of Aliada Therapeutics, including a promising Alzheimer's disease candidate, for $1.4 billion in cash. And it announced that it will buy out Nimble ...
Recently AbbVie closed its acquisition of Aliada Therapeutics, including a promising Alzheimer's disease candidate, for $1.4 ...
AbbVie, a global pharmaceutical company headquartered in North Chicago, is acquiring Madison-based Nimble Therapeutics for $200 million in cash, the companies said in a news release. AbbVie has ...
On December 18, a recent SEC filing unveiled that Kevin K Buckbee, SVP at AbbVie ABBV made an insider sell. What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission on ...
AbbVie, a drug company based in North Chicago, Illinois, is paying $200 million to acquire Madison-based Nimble Therapeutics, which is developing an oral therapy that could treat psoriasis and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback